Meropenem in Children Receiving Continuous Renal Replacement Therapy: Clinical Trial Simulations Using Realistic Covariates Publication Meropenem in Children Receiving Continuous Renal Replacement Therapy: Clinical Trial Simulations Using Realistic Covariates Meropenem is frequently prescribed in children receiving continuous renal replacement therapy (CRRT). Fluid overload is…Certara2014 年 12 月 1 日
Vigabatrin Pediatric Dosing Information for Refractory Complex Partial Seizures: Results from a Population Dose-response Analysis Publication Vigabatrin Pediatric Dosing Information for Refractory Complex Partial Seizures: Results from a Population Dose-response Analysis We predicted vigabatrin dosages for adjunctive therapy for pediatric patients with refractory complex partial seizures…Certara2014 年 12 月 1 日
Modeling and Simulation for Medical Product Development and Evaluation: Highlights from the FDA-C-Path-ISOP 2013 Workshop Publication Modeling and Simulation for Medical Product Development and Evaluation: Highlights from the FDA-C-Path-ISOP 2013 Workshop Medical-product development has become increasingly challenging and resource-intensive. In 2004, the Food and Drug Administration…Certara2014 年 12 月 1 日
Population Pharmacokinetics Analysis of Vigabatrin in Adults and Children with Epilepsy and Children with Infantile Spasms Publication Population Pharmacokinetics Analysis of Vigabatrin in Adults and Children with Epilepsy and Children with Infantile Spasms Vigabatrin is an inhibitor of γ-aminobutyric acid transaminase. The purpose of these analyses was to…Certara2014 年 11 月 1 日
A Pharmacokinetic/Viral Kinetic Model to Evaluate the Treatment Effectiveness of Danoprevir Against Chronic HCV Publication A Pharmacokinetic/Viral Kinetic Model to Evaluate the Treatment Effectiveness of Danoprevir Against Chronic HCV Certara2014 年 10 月 16 日
Lost in Centrifugation: Accounting for Transporter Protein Losses in Quantitative Targeted Absolute Proteomics Publication Lost in Centrifugation: Accounting for Transporter Protein Losses in Quantitative Targeted Absolute Proteomics In drug development, considerable efforts are made to extrapolate from in vitro and preclinical findings…Certara2014 年 10 月 1 日
Time Course of Bone Mineral Density Changes with Denosumab Compared with Other Drugs in Postmenopausal Osteoporosis: A Dose-response-based Meta-analysis Publication Time Course of Bone Mineral Density Changes with Denosumab Compared with Other Drugs in Postmenopausal Osteoporosis: A Dose-response-based Meta-analysis Our objective was to compare the time course of bone mineral density (BMD) changes at…Certara2014 年 10 月 1 日
Cardiac Safety Research Consortium: Can the Thorough QT/QTc Study Be Replaced by Early QT Assessment in Routine Clinical Pharmacology Studies? Scientific Update and a Research Proposal for a Path Forward Publication Cardiac Safety Research Consortium: Can the Thorough QT/QTc Study Be Replaced by Early QT Assessment in Routine Clinical Pharmacology Studies? Scientific Update and a Research Proposal for a Path Forward The International Conference on Harmonization E14 guidance for the clinical evaluation of QT/QTc interval prolongation…Certara2014 年 9 月 1 日
Understanding the Effect of the HCV Polymerase Inhibitor Mericitabine on Early Viral Kinetics in the Phase 2 JUMP-C and PROPEL Studies Publication Understanding the Effect of the HCV Polymerase Inhibitor Mericitabine on Early Viral Kinetics in the Phase 2 JUMP-C and PROPEL Studies Certara2014 年 8 月 21 日
Adding a Placebo Component to Your PK/PD Model in Phoenix Knowledge Base Adding a Placebo Component to Your PK/PD Model in Phoenix PK/PD modeling is an exciting are of research in clinical pharmacology. Most often we try…Certara2014 年 8 月 20 日